Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore University, German Firm To form 3-D Printing Lab For Devices

This article was originally published in PharmAsia News

Executive Summary

Germany's SLM Solutions and Singapore's Nanyang Technological University have formed an alliance centered around building a 3-D laboratory to "print" medical devices.

You may also be interested in...



UK Publishes COVID-19 Self-Test Specifications

The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level. 

Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned

Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Topics

UsernamePublicRestriction

Register

SC087195

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel